Genmab A/S

CPSE:GMAB Stock Report

Market Cap: DKK 129.3b

Genmab Past Earnings Performance

Past criteria checks 5/6

Genmab has been growing earnings at an average annual rate of 10.1%, while the Biotechs industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 19.7% per year. Genmab's return on equity is 25.9%, and it has net margins of 37.6%.

Key information

10.07%

Earnings growth rate

10.57%

EPS growth rate

Biotechs Industry Growth18.72%
Revenue growth rate19.73%
Return on equity25.86%
Net Margin37.59%
Next Earnings Update06 Nov 2025

Recent past performance updates

Recent updates

Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today

Sep 24
Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today

Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings

Jul 31
Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 11
Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

It's Unlikely That The CEO Of Genmab A/S (CPH:GMAB) Will See A Huge Pay Rise This Year

Mar 06
It's Unlikely That The CEO Of Genmab A/S (CPH:GMAB) Will See A Huge Pay Rise This Year

Genmab A/S Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Feb 17
Genmab A/S Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next
User avatar

Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers

Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals.

Revenue & Expenses Breakdown

How Genmab makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CPSE:GMAB Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 253,6471,3716241,550
31 Mar 253,2311,1405501,425
31 Dec 242,9901,0905261,343
30 Sep 242,9647025191,349
30 Jun 242,7437985011,276
31 Mar 242,5767915041,187
31 Dec 232,4406454881,130
30 Sep 232,3895904661,033
30 Jun 232,378680453979
31 Mar 232,216757422890
31 Dec 222,088785385801
30 Sep 221,580745299688
30 Jun 221,438558268683
31 Mar 221,342354228667
31 Dec 211,288452196640
30 Sep 211,232448156590
30 Jun 211,168401134541
31 Mar 211,703880119512
31 Dec 201,660781108515
30 Sep 201,73688986453
30 Jun 201,55985373417
31 Mar 2083734956378
31 Dec 1980632551358
30 Sep 1953222342317
30 Jun 1948717839291
31 Mar 1944120236250
31 Dec 1846422633220
30 Sep 1843722230191
30 Jun 1839719428174
31 Mar 1846221326164
31 Dec 1738117824137
30 Sep 1736118421126
30 Jun 1735620819110
31 Mar 1727217416101
31 Dec 162571681494
30 Sep 162211111597
30 Jun 162051021490
31 Mar 16183821481
31 Dec 151651111371
30 Sep 15116661466
30 Jun 15115691466
31 Mar 15102601266
31 Dec 14138491382

Quality Earnings: GMAB has high quality earnings.

Growing Profit Margin: GMAB's current net profit margins (37.6%) are higher than last year (29.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: GMAB's earnings have grown by 10.1% per year over the past 5 years.

Accelerating Growth: GMAB's earnings growth over the past year (71.7%) exceeds its 5-year average (10.1% per year).

Earnings vs Industry: GMAB earnings growth over the past year (71.7%) did not outperform the Biotechs industry 85.9%.

Return on Equity

High ROE: GMAB's Return on Equity (25.9%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/03 18:38
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genmab A/S is covered by 49 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew CarlsenABG Sundal Collier
Armelle MoulinAlphaValue
Xue ChenBarclays